PMGC Holdings (ELAB) Raw Materials (2023 - 2026)

PMGC Holdings (ELAB) posted Raw Materials of $62147.0 for Q1 2026, up 521.47% sequentially from $10000.0 in Q4 2025.

PMGC Holdings (ELAB) Raw Materials (2023 - 2026) Analysis & Trends

PMGC Holdings has reported Raw Materials for 4 years, with the latest figure at $62147.0 in Q1 2026.

Quarterly Raw Materials changed N/A year-over-year to $62147.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62147.0 (changed N/A YoY) and the FY2025 annual result came in at $10000.0, changed N/A from the prior year.
Raw Materials grew to $62147.0 in Q1 2026 per ELAB's latest filing, from $10000.0 in the prior quarter.
Over five years, Raw Materials peaked at $474124.0 in Q2 2024 and troughed at $10000.0 in Q4 2025.
A 4-year average of $266080.7 and a median of $305442.5 in 2023 frame the typical range for Raw Materials.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.29 Bn	132.43 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.58 Bn	78.58 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn
4	Moderna	61.87 Bn	56.73 Bn	52.00 Mn
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn
7	BioNTech SE	28.90 Bn	10.51 Bn	668.28 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-
10	PMGC Holdings	30.43 Mn	11.64 Mn	385,691.00

Download Data